SCHEMBL5006434

SCHEMBL5006434

COCOc1cc(OCOC)c(C(C)C)cc1-c1n[nH]c(=S)n1-c1cccc(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNE Q04844 1/20 0.52
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 5/20 0.46
KMT2A Q03164 2/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 5/20 0.46
GFER P55789 4/20 0.46
HSD17B10 Q99714 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
APOBEC3G Q9HC16 2/20 0.46
LMNA P02545 1/20 0.46
PRNP P04156 1/20 0.46
PPARG P37231 1/20 0.46
NCOA2 Q15596 1/20 0.46
NCOA1 Q15788 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4999280 0.91 HPGD (0.49) ALDH1A1KDM4EKMT2AHTTMEN1
SCHEMBL5002796 0.87 ADAM17 (0.47) HSP90AA1HSP90AB1ALDH1A1KDM4EKMT2A
SCHEMBL14925072 0.84 HPGD (0.48) ALDH1A1KDM4EKMT2AHTTMEN1
SCHEMBL5006438 0.81 CHRNE (0.53) CHRNEHSP90AA1HSP90AB1ALDH1A1KDM4E
SCHEMBL5002786 0.80 HSP90AA1 (0.44) HSP90AA1HSP90AB1ALDH1A1KDM4EKMT2A
SCHEMBL5002702 0.79 TDP1 (0.43) HSP90AA1HSP90AB1ALDH1A1KDM4EKMT2A
SCHEMBL5002657 0.79 HSP90AB1 (0.48) HSP90AA1HSP90AB1TDP1
SCHEMBL5003248 0.78 POLB (0.38) HSP90AA1HSP90AB1ALDH1A1KDM4EKMT2A
SCHEMBL5002720 0.77 HSP90AA1 (0.41) HSP90AA1HSP90AB1ALDH1A1KDM4EHTT
SCHEMBL14029886 0.76 HSP90AA1 (0.43) HSP90AA1HSP90AB1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116251-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
US-20130116431-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
US-20130116252-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
US-20130116253-A1 Novel HSP90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-05-09 US disclosed
EP-1857446-B1 Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer NIPPON KAYAKU KK (JP) 2013-05-01 EP disclosed
US-8399464-B2 using a triazole compound; anticancer agent NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-03-19 US disclosed
US-20080269218-A1 Novel Hsp90 Inhibitor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2008-10-30 US disclosed
EP-1857446-A1 NOVEL HSP90 INHIBITOR Nippon Kayaku Kabushiki Kaisha (JP) 2007-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116252-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 CHRNE 4848/4885HSP90AA1 4/4885HSP90AB1 1/4885
US-20130116253-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 CHRNE 4848/4885HSP90AA1 4/4885HSP90AB1 1/4885
US-20080269218-A1 Novel Hsp90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 CHRNE 4842/4885HSP90AA1 4/4885HSP90AB1 1/4885
US-20130116251-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 CHRNE 4848/4885HSP90AA1 4/4885HSP90AB1 1/4885
US-20130116431-A1 Novel HSP90 Inhibitor HSP90AB1, HSP90AB2P, HSP90B1 CHRNE 4848/4885HSP90AA1 4/4885HSP90AB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.